Stroke Care Snags $10M in Series C Financing

According to VCBeat, Stroke Care, a well-known interventional medical device company for stroke in China, completed a US$10M Series C financing, jointly invested by LYFE Capital and Sherpa Venture Capital. Das Capital acted as the exclusive financial adviser. Wang Guohui, founder and CEO of Stroke Care, said that the funds raised would be used for the development of new products and marketing of listed products to speed up the industrialization of the company.

Founded in 2016, Stroke Care is located in Shanghai Zhangjiang High-Tech Park. The company focuses on the development of new minimally invasive interventional products for the prevention and treatment of ischemic stroke. 

After four years of development, Stroke Care has built five product lines, covering mechanical thrombectomy for patients with ischemic stroke, treatments of carotid artery stenosis with ischemic stroke and hemorrhagic stroke, cardiogenic stroke prevention, vascular access products, etc. The company has developed 15 to 20 products.

Its self-developed drug-eluting balloon, which is used in rapamycin treatment within the skull, is the world's first promising product for the interventional treatment of intracranial stenosis. The self-developed stent retriever for the treatment of acute ischemic stroke, is the first domestic revascularization device as a counterpart of the latest generation of Medtronic's Solitaire platinum revascularization device. It is expected to be approved for the market in the near future.

Founded in 2015, LYFE Capital is a dedicated healthcare fund with US$1.27 billion in assets under management. Its investment focus spans biopharmaceuticals, medical devices, and diagnostics. 

Founded in 2018 and is headquartered in Beijing, China, Sherpa Venture Capital is an investment firm that focuses on the investment and cultivation of the Pharmaceutical and Biotech industry. It also specializes in the investment and management of sector leaders and innovators within the Pharma, GeneTech, MedTech, Medical services, and various sub-sectors, where the company has established robust portfolio sources, lasting value-adding cooperation and relationships, as well as mature all-cycle services with key resources.